Citigroup cuts ACADIA Pharmaceuticals target to $33 after trial miss
AI摘要
Citigroup lowered ACADIA Pharmaceuticals’ price target after remlifanserin missed its trial goal.
ACADIA shares dropped 10.5% following the mid-stage trial result.
Citigroup retained its Buy rating on ACADIA Pharmaceuticals.
Citigroup lowered its price target for ACADIA Pharmaceuticals to $33 from $40 after the company’s Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial. ACADIA shares fell 10.5%, while Citigroup maintained its Buy rating.
本网站上的信息是使用AI生成的，我们无法保证其准确性。
请仅作为参考信息使用。
Citigroup cuts ACADIA Pharmaceuticals target to $33 after trial miss - CoinPost Terminal